PATENT CLAIM ANALYSIS

Application Number: 16076479
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["424", "136100"]

Abstract:
The present invention relates to engineered cells, engineered chimaeric antigen ligands (CALs), novel uses of multi-specific binding agents for bridging cells, and methods of therapy. The invention also provides variation-matched engineered cells.

Claim (Index 101):
A method of carrying out immunotherapy of a cancer in a human subject, wherein the method comprises administering to the subject an immune cell, wherein the immune cell expresses a transmembrane protein comprising an engineered combination of\n i. an extracellular part comprising a binding moiety that is linked to a transmembrane domain; and ii. an intracellular part comprising a first signaling domain for intracellular signaling; wherein the binding moiety (iii) binds to an extracellular antigen comprised by a cancer cell that is comprised by the subject to target the immune cell to the target cell, or (iv) binds to a bridging agent, wherein the bridging agent further binds to a cancer cell that is comprised by the subject to target the immune cell to the target cell, whereby said intracellular signaling is triggered and immunotherapy of the cancer is carried out; wherein the genome of the immune cell comprises one, more, or all of A to C: A. an endogenous nucleotide sequence encoding a CD3 zeta intracellular domain comprising SEQ ID NO: 9 or wherein the endogenous sequence has been inactivated or knocked-out; and a nucleotide sequence encoding a CD3 zeta intracellular domain of the transmembrane protein which comprises SEQ ID NO: 9; B. an endogenous nucleotide sequence encoding a CD28 intracellular domain comprising SEQ ID NO: 15 or wherein the endogenous sequence has been inactivated or knocked-out; and a nucleotide sequence encoding a CD28 intracellular domain of the transmembrane protein which comprises SEQ ID NO: 15; C. an endogenous nucleotide sequence encoding a 4-1BB intracellular domain comprising SEQ ID NO: 18 or wherein the endogenous sequence has been inactivated or knocked-out; and a nucleotide sequence encoding a 4-1BB intracellular domain of the transmembrane protein which comprises SEQ ID NO: 18.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 96.0
- Lexical Diversity: 1.34483
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15866222', '15934770', '15105074', '15637734', '15106783']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7391443776361688
- 35 USC 102 Novelty (BERT): 0.5155675068228588
- Combined Prediction Score: 0.7167866905548379
- Mean Citation Score: 319.32395
- Max Citation Score: 322.89294
- Similarity Product: 260.9648460746169

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test